Oregon is currently home to 1203 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954
Recruiting
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: University of Oregon, Portland, Oregon
Conditions: Myasthenia Gravis, Myasthenia Gravis, MuSK
Register for Updates
ASSESS ALL ALS Study
NCT06578195
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Providence ALS Center, Portland, Oregon
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
NCT06402201
Recruiting
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Providence Cancer Institute, Portland, Oregon
Conditions: Select Advanced Solid Tumors
Register for Updates
An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
NCT06079697
Recruiting
This clinical trial evaluates a prehabilitation exercise intervention for improving mobility and recovery outcomes in patients undergoing surgery for head and neck cancer. Prehabilitation focuses on optimizing health before surgery in order to improve outcomes after surgery. Prehabilitation may include aspects of nutrition, exercise, mental health, or a combination of these. Exercise has been proven to improve anxiety, depression, fatigue, health related quality of life, and physical function am... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/11/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Head and Neck Carcinoma
Register for Updates
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
NCT06075745
Recruiting
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Oregon Health & Sciences University, Portland, Oregon
Conditions: Liver Transplant
Register for Updates
Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation
NCT06381674
Recruiting
Current clinical assessment tools are often not sensitive enough to detect and treat some subtle (yet troubling) problems after mTBI. In this study, the investigators will use wearable sensors to both assess and treat people with mTBI. Specifically, the investigators will provide immediate feedback, with visual and/or auditory, on movement quality during physical therapy. This immediate feedback on performance may improve outcomes as the investigators will measure multiple body segments includin... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/10/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Mild Traumatic Brain Injury, Concussion, Rehabilitation, Balance Impairment
Register for Updates
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Oregon Health & Science University (OHSU), Portland, Oregon
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Register for Updates
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
NCT06932237
Recruiting
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. The investigators' research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) ass... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Neuro-PASC, Long COVID
Register for Updates
OTAGO Exercise Program and Motivational Interviewing
NCT06931067
Recruiting
The goal of this study is to see if OTAGO instructors, who have been trained in a special communication method called motivational interviewing, can help older adults start and stick with the OTAGO exercise program. The results will help guide future research on how behavior change techniques can support other fall prevention strategies.
Gender:
ALL
Ages:
Between 60 years and 120 years
Trial Updated:
04/09/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Fall Risk Factors, Physical Activity, Engagement, Patient, Community-dwelling Older Adults
Register for Updates
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110
Recruiting
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Willamette Valley, Eugene, Oregon
Conditions: NSCLC
Register for Updates
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
NCT05919329
Recruiting
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Register for Updates